Manufacturer
ORION CORP
Contents
Budesonide
Indication
Asthma
Instruction
As dry powder inhaler: 200-800 mcg daily as a single dose or in 2 divided doses.
Drug interaction
Diminished therapeutic effects of vaccines. Increased systemic exposure and side effects with CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, HIV protease inhibitors, clarithromycin, cobicistat). Decreased systemic exposure with CYP3A4 inducers (e.g. carbamazepine, rifampicin). Enhanced K excretion and aggravated hypokalaemia with diuretics. May potentiate effects of cardiac glycosides. May reduce uptake with colestyramine or antacids.
Malaysia
